Similar to steroidal MRAs, evidence supports a protective role of finerenone in anti-inflammatory, anti-fibrotic and anti-remodeling in both kidney and cardiac tissues, as well as reducing renal and myocardial hypertrophy, BNP, and proteinuria in rodent models, which may be associated with its benefits in renal outcomes [4, 36, 37]. This evidence concerns the gene NPPB and cardiac hypertrophy.